Cognitive behavioural therapy based self help
OtherComparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
NCT Number: NCT01532037
The purpose of this study is to determine if cognitive behavioural therapy (CBT) based self help is effective for the management of symptoms of fatigue in Multiple Sclerosis (MS).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Fife Rehabilitation Service, Leven, Scotland, United Kingdom
Background: Fatigue is a common disabling symptom in patients with Multiple Sclerosis (MS). Cognitive behavioural therapy (CBT) has been shown to be effective in the reduction of fatigue in MS and CBT-based self-help has been shown to be effective as a low intensity intervention for anxiety and depression.
Objectives: To evaluate the effectiveness of a CBT based self-help workbook at reducing perceived impact of fatigue in a clinical sample of MS patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
Usual care from healthcare professionals with regard to patients symptoms of fatigue
Time frame: 5 time points at 0, 8, 20, 32 & 60 weeks.
The Modified Fatigue Impact Scale (MFIS) consists of 21 items selected from the Fatigue Impact Scale (FIS; Fisk, Ritvo, Ross, Haase, Murray, & Schlech, 1994), a multidimensional scale developed to assess the perceived impact of fatigue on a variety of daily activities. The items of the MFIS can be combined into three subscales (Physical, Cognitive, and Psychosocial), as well as into a total MFIS score. All items are scaled so that higher scores indicate a greater impact of fatigue on a patient's activities. Measures will be taken at 5 time points to assess change over time.
Time frame: 5 time points at 0, 8, 20, 32 & 60 weeks
36-Item Short Form Survey Instrument (SF 36, Ware et al.1993) consists of 36 questions measuring functional health and well-being from the patient's point of view. Scores are split into two summary measures (physical health and mental health) and within the two summary measures there are eight scales which include. The eight scales are made up of; physical functioning, role limitations due to physical functioning, bodily pain, general health, vitality, social functioning, role limitations due to emotional functioning and mental health.
Time frame: 5 time points at 0, 8, 20, 32 & 60 weeks
Time frame: 5 time points at 0, 8, 20, 32 & 60 weeks
Is a 6-item scale which is adapted from the original 33 item scale (Lorig et al. 1996). The 6-item scale was developed so it would be less burdensome for patients. The 6- item scale covers areas of symptom control, role function, emotional functioning and communicating with physicians.
University of Edinburgh
Other
A Randomised Controlled Trial of Cognitive Behavioural Therapy Based Self Help for Fatigue in Multiple Sclerosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07680738
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Mexico City, Mexico
View Trial DetailsNCT04267926
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Portland, Oregon, United States
View Trial DetailsNCT06783413
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Tokat Province, Turkey (Türkiye)
View Trial DetailsNCT05848323
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Seattle, Washington, United States
View Trial Details